Australian Clinical Labs Limited News - ACL

Nestle 08 Net Profit Jumps 69% On Windfall; Oulook Cautious

Nestle SA (NESN.VX), the world's largest food and beverages company, Thursday gave a guarded outlook for 2009 even though it raised its dividend...

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Swiss food giant Nestle SA (NESN.VX) said Thursday it had '08 net profit of CHF18 billion, up 69%, citing strong organic growth and the windfall...

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Swiss food giant Nestle SA (NESN.VX) said Thursday it had '08 net profit of CHF18 billion, up 69%, citing strong organic growth and the windfall...

Nestle '08 Net Profit Up 69%, Sees Growth -2-

Powdered and liquid beverages: sales of CHF18.9 billion, 12.8% organic growth and 7.4% real internal growth. The EBIT margin declined by 30 basis...

Alcon Trims Staff Amid Generic Competition For Eye Drug

By Jon Kamp Of DOW JONES NEWSWIRES Eye-care company Alcon Inc. (ACL) is laying off about 260 from its 15,000-strong global work force as it deals...

Alcon 4Q EPS Up 12%, Sees FY09 Non-GAAP EPS Shy Of Street View

Alcon Inc.'s (ACL) fourth-quarter earnings per share rose 12.8% as total sales climbed 2% with organic sales up 6.4%. "The long term strategic...

Abbott Standing Pat Now, But Vision Deal Could Yield More

By Jon Kamp Of DOW JONES NEWSWIRES Now that Abbott Laboratories (ABT) is buying an eye-health business, through its proposed acquisition of...

Significant Milestone on Path to Commercialisation of Fondaparinux

Australian drug developer, Alchemia Limited (ASX:ACL), today announced the achievement of a significant milestone towards the...

Key Fondaparinux Patent Allowed by U.S. Patent Office

Australian drug developer Alchemia Limited (ASX:ACL) today announced it had received a ?notice of allowance? for the United...

Alchemia Patents Granted for Generic Fondaparinux

Alchemia Ltd. (ASX:ACL) announces the granting of the first two patents in the ?Synthetic Heparin Oligosaccharide? family of...

Alchemia Announces Appointment of Non Executive Director

The Board of Alchemia Limited (ASX:ACL) is pleased to announce the appointment of Mr Carlo Montagner to the position of non...

Alchemia Approaching Several Key Milestones in 2008

Alchemia Limited (?the Company?) (ASX:ACL) today announced its half year results for the six months ended 31 December 2007...

Alchemia Announces Successful Pre-IND Meeting With the US FDA

Australian drug developer, Alchemia Limited (ASX:ACL), today announced agreement on the HA-irinotecan clinical development...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Australian Clinical Labs Limited (ACL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ACL News

Nestle 08 Net Profit Jumps 69% On Windfall; Oulook Cautious

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Nestle '08 Net Profit Up 69%, Sees Growth -2-

Alcon Trims Staff Amid Generic Competition For Eye Drug

Alcon 4Q EPS Up 12%, Sees FY09 Non-GAAP EPS Shy Of Street View

Abbott Standing Pat Now, But Vision Deal Could Yield More

Significant Milestone on Path to Commercialisation of Fondaparinux

Key Fondaparinux Patent Allowed by U.S. Patent Office

Alchemia Patents Granted for Generic Fondaparinux

Alchemia Announces Appointment of Non Executive Director

Alchemia Approaching Several Key Milestones in 2008

Alchemia Announces Successful Pre-IND Meeting With the US FDA

ACL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Australian Clinical Labs Limited (ACL) News

Australian Clinical Labs Limited (ACL)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ACL News

Nestle 08 Net Profit Jumps 69% On Windfall; Oulook Cautious

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Nestle '08 Net Profit Up 69%, Sees Growth Slowdown In '09

Nestle '08 Net Profit Up 69%, Sees Growth -2-

Alcon Trims Staff Amid Generic Competition For Eye Drug

Alcon 4Q EPS Up 12%, Sees FY09 Non-GAAP EPS Shy Of Street View

Abbott Standing Pat Now, But Vision Deal Could Yield More

Significant Milestone on Path to Commercialisation of Fondaparinux

Key Fondaparinux Patent Allowed by U.S. Patent Office

Alchemia Patents Granted for Generic Fondaparinux

Alchemia Announces Appointment of Non Executive Director

Alchemia Approaching Several Key Milestones in 2008

Alchemia Announces Successful Pre-IND Meeting With the US FDA

ACL Discussion

Your Recent History